1. Scrip
  2. >>Business

Nuvelution Puts Business Model Into Action With Teva/Austedo Deal

 
• By Joseph Haas

Focused on drug development risk-sharing partnerships, Nuvelution signs its first partnership, with Teva, to conduct Phase III development of recently approved Austedo for pediatric Tourette syndrome.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

The brain-child of Clarus Ventures and in partnership with industry heavy-hitters like Chris Viehbacher and Arthur Higgins, privately held Nuvelution Pharma Inc. finally gets to put its business model into action through a development partnership with Teva Pharmaceutical Industries Ltd. to perform late-stage studies of Austedo in pediatric Tourette syndrome.

Employing a risk-sharing framework, in which Nuvelution will fund and manage the Phase III program – with hands-on work being...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Industry’s Vaccines Pipeline In A Changing Regulatory Landscape

 
• By Jessica Merrill

More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By Kevin Grogan

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By Andy Smith

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.